Discover 3,059 paid clinical trials in Brockton, Massachusetts. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 3,059
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
for
Moderately to Severely Active Crohn Disease
Location: New Bedford MA, Uniontown PA, Roanoke VA, Detroit MI,
Sponsor: Abivax S.A.
Sex: All
Age: 18 - 70+
Code: NCT06456593
Phase 2, Recruiting
Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acne
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion
for
Immunoglobulin Light Chain (AL) Amyloidosis
Location: Boston MA, New York NY, Winston-Salem NC, Charlotte NC,
Sponsor: AbbVie
Sex: All
Age: 18+
Code: NCT06158854
Phase 1, Phase 2, Recruiting
Testing Pediatric Rheumatology Diagnostic Decision Support in Clinical Use
Location: Boston MA, Rochester NY, Chapel Hill NC, Detroit MI,
Sponsor: Opna Bio LLC
Sex: All
Age: 18+
Code: NCT06433947
Phase 1, Recruiting
ATLAS (AltaValve) Pivotal Trial
for
Mitral Regurgitation, Mitral Insufficiency,
Location: Boston MA, The Bronx NY, New York NY, Morristown NJ,
Sponsor: 4C Medical Technologies, Inc.
Sex: All
Age: 18+
Code: NCT06465745
Recruiting
A Study of Codrituzumab in Children and Young Adults With Solid Tumors and Have Not Responded to Treatment or Have Come Back After Treatment
for
Primary Extra-cranial Solid Tumor,
Location: Boston MA, New York NY, Cincinnati OH, Atlanta GA,
Sponsor: Memorial Sloan Kettering Cancer Center
Sex: All
Age: 1 - 21
Code: NCT04928677
Phase 1, Recruiting
Glaucoma Drainage Device and Endothelial Cell Loss Compare Trial
for
Glaucoma
Location: Boston MA, Baltimore MD, Buffalo NY, Toronto,
Sponsor: University of Pennsylvania
Sex: All
Age: 18+
Code: NCT05924477
Recruiting
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer